Trial Profile

A Phase 1 Study of ENMD-2076 in Patients With Relapsed or Refractory Hematological Malignancies.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 04 Aug 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ENMD 2076 (Primary)
Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions
Sponsors CASI Pharmaceuticals; EntreMed

Most Recent Events

12 Jul 2016 Results published in the Investigational New Drugs
03 Aug 2011 Actual end date (1 May 2011) added as reported by ClinicalTrials.gov.
03 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com